Clinical Progress Drives Galectin Shares Up Post-NAVIGATE Data

Company Performance - Galectin Therapeutics Inc. reported a GAAP EPS of -$0.13 for Q3 2025, translating to a net loss of $8.2 million for the quarter [1] - The decline in earnings was primarily attributed to increased research and development and operating expenses [1] Analyst Background - The analyst has a Master's degree in Cell Biology and extensive experience in drug discovery, focusing on cell culture, assay development, and therapeutic research [1] - The analyst has been active in the investing space for five years, with a focus on biotechnology companies that are innovating through novel mechanisms of action and first-in-class therapies [1] - The approach emphasizes evaluating the science behind drug candidates, the competitive landscape, clinical trial design, and potential market opportunities while balancing financial fundamentals and valuation [1]